Aspida Life Sciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Aspida Life Sciences Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $366.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aspida Life Sciences Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $366.6K Trade | TransData Nexus

Aspida Life Sciences Private Limited

Indian Pharmaceutical Exporter · Antiviral & HIV Medications Specialist · $366.6K Total Trade · DGFT Verified

Aspida Life Sciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $366.6K across 3 products in 2 therapeutic categories. Based on 81 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Sofosbuvir ($181.5K), Velpatasvir ($146.1K), Gefitinib ($39.0K).

Aspida Life Sciences Private Limited — Export Portfolio & Destination Treemap

Aspida Life Sciences Private Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Aspida Life Sciences Private Limited? — Company Overview & Market Position

Aspida Life Sciences Private Limited is a privately held pharmaceutical company incorporated on October 23, 2020, in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24304DL2020PTC372058. Its authorized and paid-up capital stands at ₹1.5 million each. The registered office is located at B-392, Upper Ground Floor, Nirman Vihar, New Delhi, Delhi 110092.

The company's primary focus is on the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. In the fiscal year 2022-2023, Aspida Life Sciences reported a total export value of $367,000 USD, encompassing 81 shipments across three products in two therapeutic categories. The top three products exported were Sofosbuvir ($182,000), Velpatasvir ($146,000), and Gefitinib ($39,000). The portfolio is heavily concentrated, with the top five products accounting for 100% of the export value.

What Does Aspida Life Sciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Sofosbuvir$181.5K 2

Product Portfolio — Top 3 by Export Value

Aspida Life Sciences Private Limited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Sofosbuvir	Antiviral & HIV Medications	$181.5K	37	0.4%	9
2	Velpatasvir	Antiviral & HIV Medications	$146.1K	28	0.6%	7
3	Gefitinib	Advanced Oncology	$39.0K	16	0.6%	9

Aspida Life Sciences Private Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $366.6K. The top category is Antiviral & HIV Medications (89.4% of portfolio), followed by Advanced Oncology (10.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Aspida Life Sciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Aspida Life Sciences' manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company's export activities suggest that it may operate manufacturing units compliant with international standards, but without explicit information, a comprehensive assessment cannot be made.

3Key Leadership

The company's leadership comprises Anant Rai and Garima Gupta, both serving as directors. Anant Rai was appointed on December 31, 2021, and Garima Gupta on March 15, 2023. Their roles and professional backgrounds are not detailed in the available sources. Further information on other key executives is not publicly accessible.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Aspida Life Sciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Aspida Life Sciences' export data indicates a focus on antiviral and oncology medications, with Sofosbuvir and Velpatasvir being prominent products. However, specific regulatory approvals or market access statuses in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The absence of detailed regulatory information suggests that the company may not have established a significant presence in these markets.

2Emerging Markets

The company's export activities, particularly in antiviral and oncology medications, position it to potentially serve emerging markets in Africa, Latin America, and Southeast Asia. However, without explicit data on WHO prequalification or other regulatory certifications, it is challenging to assess Aspida Life Sciences' penetration and market access in these regions.

3Geographic Strategy

Aspida Life Sciences' export portfolio is highly concentrated, with the top five products accounting for 100% of the export value. This suggests a focused geographic strategy, potentially targeting markets with high demand for antiviral and oncology medications. The lack of diversification in the product portfolio may expose the company to risks associated with market fluctuations and regulatory changes in these specific therapeutic areas.

Aspida Life Sciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

There is no publicly available information regarding Aspida Life Sciences' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The absence of such data indicates that the company may not have established a significant presence in the U.S. market or may not have pursued FDA approvals for its products.

2WHO & EU GMP

Information regarding Aspida Life Sciences' compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The lack of such certifications may limit the company's ability to access certain international markets that require these standards.

3CDSCO & Indian Regulatory

Specific details about Aspida Life Sciences' manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs) are not publicly disclosed. The company's export activities suggest compliance with Indian regulatory requirements, but without explicit information, a comprehensive assessment cannot be made.

Aspida Life Sciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Aspida Life Sciences operates in the competitive pharmaceutical export market, focusing on antiviral and oncology medications. While specific competitors are not identified in the available data, the company's concentrated product portfolio may face competition from other manufacturers offering similar products. The lack of diversification in the product range could impact the company's ability to compete effectively in a dynamic market.

2Key Differentiators

Aspida Life Sciences' focus on antiviral and oncology medications, particularly Sofosbuvir and Velpatasvir, positions it in specialized therapeutic areas. However, the company's highly concentrated product portfolio may limit its ability to leverage a broader range of market opportunities.

3Strategic Position

Aspida Life Sciences appears to focus on exporting finished pharmaceutical formulations in the antiviral and oncology sectors. The company's strategic direction is not explicitly detailed in the available sources, and the lack of diversification in its product portfolio may pose challenges in adapting to changing market demands.

Buyer Due Diligence Brief — Evaluating Aspida Life Sciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

The available data does not provide sufficient information to assess Aspida Life Sciences' overall track record, export volume consistency, or reliability indicators. The company's export activities suggest a focus on specific therapeutic areas, but without detailed performance metrics, a comprehensive evaluation cannot be made.

2Certifications to Verify

Importers should verify the following certifications when considering products from Aspida Life Sciences:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA) for import into the United States.

WHO-GMP: Ensure that the manufacturing facilities comply with World Health Organization Good Manufacturing Practice (WHO-GMP) standards.

EU GMP: Verify that the products meet European Union Good Manufacturing Practice (EU GMP) requirements for import into EU member states.

Frequently Asked Questions — Aspida Life Sciences Private Limited

How many pharmaceutical products does Aspida Life Sciences Private Limited export from India?

Aspida Life Sciences Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Sofosbuvir ($181.5K), Velpatasvir ($146.1K), Gefitinib ($39.0K). Total export value is $366.6K.

What is Aspida Life Sciences Private Limited's total pharmaceutical export value?

Aspida Life Sciences Private Limited's total pharmaceutical export value is $366.6K, based on 81 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Aspida Life Sciences Private Limited cover?

Aspida Life Sciences Private Limited exports across 2 therapeutic categories. The largest are Antiviral & HIV Medications (89.4%, 2 products), Advanced Oncology (10.6%, 1 products).

Get Full Aspida Life Sciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.